517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Natalie Cook(Manchester Academic Health Science Centre), Ruth Plummer(National Health Service), Alastair Greystoke(Newcastle University), Rille Pihlak(University of Manchester), Neil Harris(Freeman Hospital), Juanita Lopez(Institute of Cancer Research), Sarah P. Blagden(Churchill Hospital), Craig Tilston(Redx Pharma (United Kingdom)), Azam Naderi(Churchill Hospital), Farasat Kazmi(University of Oxford), Debashis Sarker(King's College - North Carolina), Caroline Phillips(Redx Pharma (United Kingdom)), A. Saunders(Redx Pharma (United Kingdom)), George Nintos(Guy's and St Thomas' NHS Foundation Trust), Jane Robertson(AstraZeneca (United Kingdom)), R. Shinde(Royal Marsden Hospital), Louise Goodwin(Redx Pharma (United Kingdom)), Adele Franco(University of Manchester), Simon A. Woodcock(Redx Pharma (United Kingdom))
Cited by 10
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406